Articles scientifiques

131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.

Auteurs : Jungels C, Karfis I
Année : 2021
Journal : Curr Opin Oncol
Volume : 33
Pages : 33-39

Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study.

Auteurs : Thibaud V, Denève L, Dubruille S, Kenis C, Delforge M, Cattenoz C, Somme D, Wildiers H, Pepersack T, Lamy T, Bron D
Année : 2021
Journal : J Geriatr Oncol
Volume : 12
Pages : 902-908

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Auteurs : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.

Auteurs : R Ferreira A, Ferreira S, Lambertini M, Maurer C, Martel S, Costa L, Ponde N, de Azambuja E
Année : 2021
Journal : Eur J Cancer
Volume : 144
Pages : 351-359

RTK Inhibitors in Melanoma: From Bench to Bedside.

Auteurs : Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem G
Année : 2021
Journal : Cancers (Basel)
Volume : 13

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Auteurs : Wang X, Suppa M, Bruderer P, Sirtaine N, Aspeslagh S, Kerger J
Année : 2021
Journal : Case Rep Oncol
Volume : 14
Pages : 861-867

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Année : 2021
Journal : BMC Cancer
Volume : 21
Pages : 1292

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.

Auteurs : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S
Année : 2021
Journal : Front Mol Biosci
Volume : 8
Pages : 673042

Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.

Auteurs : Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, Gnant M, Günthert A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauerc M, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radosevic-Robin N, Sager P, Steyerova P, Tausch C, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P
Année : 2021
Journal : Lancet Oncol
Volume : 22
Pages : e18-e28

Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis.

Auteurs : Dumont L, Salaroli A, Dal Lago L, Gil T, Pepersack T
Année : 2021
Journal : Eur J Case Rep Intern Med
Volume : 8
Pages : 002425

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer.

Auteurs : Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P
Année : 2021
Journal : Cancer Treat Rev
Pages : 102208

Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer.

Auteurs : Wrona E, Potemski P, Sclafani F, Borowiec M
Année : 2021
Journal : Arch Immunol Ther Exp (Warsz)
Volume : 69
Pages : 2

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.

Auteurs : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 784947

Impact of HIV infection on baseline characteristics and survival of women with breast cancer.

Auteurs : Brandão M, Bruzzone M, Franzoi MA, de Angelis C, Eiger D, Caparica R, Piccart-Gebhart M, Buisseret L, Ceppi M, Dauby N, Carrilho C, Lunet N, de Azambuja E, Lambertini M
Année : 2021
Journal : AIDS
Volume : 35
Pages : 605-618

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.

Auteurs : Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S
Année : 2021
Journal : Expert Opin Biol Ther
Volume : 21
Pages : 945-962

Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Auteurs : Agostinetto E, Ceppi M, Bruzzone M, Lambertini M, de Azambuja E
Année : 2021
Journal : Eur J Cancer
Volume : 155
Pages : 303-306

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.

Auteurs : Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, Munzone E, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini E, Gombos A, Deleu I, Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson A, Graas MP, Barber M, Fontaine C, Loibl S, Gavilá J, Kuroi K, Müller B, OReilly S, Di Leo A, Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 504-512

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

Auteurs : Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart-Gebhart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100117

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Auteurs : Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL
Année : 2021
Journal : Ther Adv Med Oncol
Volume : 13
Pages : 17588359211045860

Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.

Auteurs : Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, DHondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A
Année : 2021
Journal : Cancer Med
Volume : 10
Pages : 4366-4374